Global Pipeline Review for Optic Neuritis - H2 2019 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Optic Neuritis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive information on the therapeutics under development for Optic Neuritis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Optic Neuritis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 1, 4 and 4 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Optic Neuritis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Optic Neuritis (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Optic Neuritis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

• Bionure Farma SL
• Commence Bio Inc
• EnhanX Biopharm Inc
• Japan Innovative Therapeutics Inc
• Meta-IQ ApS
• Mitochon Pharmaceuticals Inc
• Noveome Biotherapeutics Inc
• Teijin Pharma Ltd

Scope:

• The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuritis (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Optic Neuritis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Optic Neuritis (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Optic Neuritis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuritis (Ophthalmology)

Key Topics Covered:

• Introduction
• Report Coverage
• Optic Neuritis - Overview
• Optic Neuritis - Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Optic Neuritis - Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Optic Neuritis - Companies Involved in Therapeutics Development
• Bionure Farma SL
• Commence Bio Inc
• EnhanX Biopharm Inc
• Japan Innovative Therapeutics Inc
• Meta-IQ ApS
• Mitochon Pharmaceuticals Inc
• Noveome Biotherapeutics Inc
• Teijin Pharma Ltd
• Optic Neuritis - Drug Profiles
• Optic Neuritis - Dormant Projects
• Optic Neuritis - Discontinued Products
• Optic Neuritis - Product Development Milestones
• Appendix
  

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/bypswy